News | February 15, 2024
Ashland launches iSolve information on demand for F&B customers
iSolveSM information on demand is the result of our focus on customer relationship
iSolveSM information on demand is the result of our focus on customer relationship
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
These re-agent and diagnostic test kits come with 99.7% accuracy
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Subscribe To Our Newsletter & Stay Updated
